Kedrion donates 1 million IU of FIX to support WHF Humanitarian Aid Program
The aim is to broaden access to haemophilia treatment regardless of the patients’ geographical location.
Festival della Salute, the Health Festival: Kedrion supports a workshop dedicated to the Italian Blood System and to self-sufficiency in plasma-derived products
Kedrion, a biopharmaceutical company specialised in the development, production and distribution of plasma-derived products, has been involved in the organisation of a workshop called “The Italian Blood System, towards self-sufficiency in plasma-derived products”, due to take place in the Sala dell’Annunziata of the Cloister of St Augustine in Pietrasanta, on Sunday, September 29th, as part
Italian Blood System, Kedrion supports FIDAS in the “Coast to Coast” initiative
The first FIDAS Coast to Coast, an initiative developed by the Italian Federation of Blood Donors’ Associations (FIDAS, Federazione Italiana Associazioni Donatori di sangue), with Kedrion’s support and contribution, will officially start on 7th July. Presented yesterday at a press conference in Rome, the event consists of a journey on two sailboats that, sailing all
Kedrion supports World Blood Donor Day
With the slogan "Give the gift of life, donate blood", today June 14th has been proclaimed World Blood Donor Day, first celebrated by the World Health Organisation in 2004 to coincide with the birthday of Karl Landsteiner, the discoverer of blood groups, to raise people’s awareness of the importance of donating blood. In Italy too,
Kedrion’s CEO, newly elected chairman of PPTA, opens the PPTA Plasma Protein Forum
Paolo Marcucci, President and CEO of Kedrion and newly elected Chairman of the Plasma Protein Therapeutics Association (PPTA), opened the PPTA Plasma Protein Forum 2013. This is one of the most important events that the world association of manufacturers of plasma-derived medicinal products organises every year to present the main challenges that the industry is
Kedrion presents the new Factor VIII for the Hungarian market
Today, at the Hungarian Academy of Sciences in Budapest, a scientific symposium celebrated the launch on the Hungarian market of the new plasma-derived product Factor VIII by Human BioPlazma, Kedrion Group’s Budapest-based subsidiary, which runs the production plant of Gödöllő. Manufactured at the production plant of Bolognana through the purification of an intermediate product received
Haemopilia, Kedrion supports the workshop on the efficiency of the blood system
Vicenza hosted the workshop “The Blood System in Italy: Criticalities and Resources in the Treatment of Haemophilia”, organised by professor Francesco Rodegherio, Director of Cellular Therapies and Haematology at Ospedale San Bortolo of Vicenza, with Kedrion’s educational support. The workshop was attended by clinicians (Haemophilia Centres, Regional Blood Centres, Transfusion Centres, National Blood Centre), pharmacists,
Grifols trnasfers to Kedrion the management of the plasma fractionation plant of Melville (USA), owned by Kedrion
Kedrion announces that, effective 1st July, 2013, Grifols S.A. will complete the transfer to Kedrion of all the operations for managing the plasma fractionation plant of Melville, State of New York (USA), owned by Kedrion. This action is part of the agreements entered into in 2011, included in the Consent Agreement of the Federal Trade
Kedrion supports initiatives for World Haemophilia Day. Partner in a project for export of blood-derived products from national plasma for humanitarian purposes
Kedrion confirms its support of the World Haemophilia Day, an initiative that is now in its 9th year in Italy and is usually celebrated on 17th April, aimed to raise awareness of haemophilia and similar conditions. The slogan chosen by the World Federation of Haemophilia (WFH) for 2013, again, is “Close the Gap”, a catchphrase
Agreement with Entegrion for the development and marketing of Resusix™, a virus inactivated spray-dried plasma
Kedrion Melville Inc., a US-based company owned by Kedrion, entered into an agreement with the US-based company Entegrion Inc. for the development and marketing of Resusix™, a virus inactivated spray-dried plasma, treated with solvent-detergent, to be used as a replacement of frozen fresh plasma. The Phase-I clinical trials that have recently been authorised by the
